In T2DM patients with low ejection-fraction HF and HbA1cabove target despite triple therapy, QUADRUPLE therapy including metformin, an SGLT2 inhibitor, a GLP-1 RA and a fourth antidiabetic agent (AD) or insulin-based therapy is recommended to improve blood glucose control. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.